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Abstract Betulinic acid (BetA) is a plant-derived penta-
cyclic triterpenoid that exerts potent anti-cancer effects in
vitro and in vivo, but is non toxic to untransformed cells. In
our previous study we observed that BetA consistently
induced cell death in a broad panel of tumor cell lines.
Apoptosis induced by BetA involves activation of caspases,
PARP cleavage and DNA fragmentation and was suggested
to depend on the mitochondrial pathway. However, con-
flicting results have been reported with respect to the role
of the pro- and anti-apoptotic members of the Bcl-2 family,
which are often aberrantly regulated in tumors and thereby
confer growth and survival advantages. Here we show that
BetA-induced apoptosis critically depends on the release of
cytochrome c from the mitochondria and formation of the
apoptosome. Nevertheless, over-expression of Bcl-2 or
Bcl-XL only provides limited protection against BetA-
induced apoptosis. More importantly, Bax/Bak deficient
cells are as sensitive to BetA as their wild-type counter-
parts, suggesting that cytochrome c is released in a non-
classical fashion. In agreement, pre-incubation with
cyclosporin A indicated a crucial role for the mitochondrial
permeability transition pore (PT) in the induction of
apoptosis. Our observations therefore indicate that BetA
affects mitochondria and induces cytochrome c release
directly via PT Pore. This is only temporarily prevented by
anti-apoptotic members of the Bcl-2 family, but indepen-
dent of Bax and Bak. These findings help to explain the
remarkable broad efficacy of BetA against tumor cells of
different origin and its effect in tumor cells that are resis-
tant to other chemotherapeutic agents.
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Introduction
Betulinic acid (BetA) is a naturally occurring triterpenoid
that has been initially described to specifically kill mela-
noma cells via induction of apoptosis [1] and was later
shown to have specificity for neuroectoderm-derived
tumors. However, it is becoming clear that its efficacy
extends to many other cancer cell lines derived from
a variety of different malignancies such as leukemia,
prostate, ovarian, breast, lung, and colon cancer [2–6].
Importantly, BetA-induced apoptosis appears to be inde-
pendent of p53 [6–8], but does show remarkable selectivity
for tumor cells over non-transformed cells.
The extrinsic or death receptor pathway is not involved
in BetA-induced apoptosis [9]. However, formation of
reactive oxygen species (ROS) and a decrease in the
mitochondrial membrane potential have been repeatedly
associated with BetA treatment [4, 10, 11], which promp-
ted the hypothesis that BetA induces apoptosis via the
mitochondrial pathway [12–14]. This pathway is normally
regulated by a carefully balanced interplay between pro-
and anti-apoptotic members of the Bcl-2 family.
Over-expression of pro-survival molecules, such as Bcl-2,
Bcl-XL or Mcl-1 or deletion of pro-apoptotic members,
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such as Bax and Bak, or alternatively deregulation of
BH3-only molecules like Bim or Puma, is often observed
in tumors and causes resistance of these cells to intrinsic
death stimuli [15].
In agreement with a role for the mitochondria in BetA-
induced apoptosis is the observation that over-expression
of Bcl-2 or Bcl-XL prevents BetA-induced cytochrome c
release, caspase activation and PARP cleavage in SHEP
neuroblastoma cells [12, 13]. However, separate studies
have shown that BetA rather increases the expression of
Bcl-2, but can also modulate the expression of other pro-
and anti-apoptotic Bcl-2 family members with distinct
outcomes. For instance, Mcl-1 was strongly induced in
melanoma cells after treatment with BetA [7], while
expression of Bcl-XS and Bax were induced in neuro-
blastoma cells after treatment with BetA [7, 9]. These
conflicting observations make it difficult to assess the role
of the Bcl-2 family in BetA-induced apoptosis. Neverthe-
less, the broad anti-tumor effect of BetA renders it unlikely
that induction of apoptosis would strictly depend on the
classical Bcl-2 regulated mitochondrial pathway, as this is
often disrupted in tumor cells [7, 15]. Previously we have
shown that in Jurkat T leukemia cells apoptosis is induced
upon incubation with BetA. Both classical and non-
classical pathways to apoptosis exist [7, 16, 17] but the
mechanism used by BetA remains incompletely defined.
We therefore set out to delineate the signaling pathway and
specifically the role of the Bcl-2 family regulated pathway
in BetA-induced apoptosis in further detail. We show that
Bcl-2 does not provide effective protection against BetA-
induced apoptosis, especially not at later time points.
Moreover, for the first time, we demonstrate that Bax/Bak
double deficient mouse embryonic fibroblasts (Bax/Bak
DKO MEFs) display cytochrome c release, caspase acti-
vation and PARP cleavage upon BetA treatment. This
indicates that BetA does not induce a classical mitochon-
drial pathway to apoptosis. The mitochondria are critically
involved though, as inhibition of the mitochondrial per-
meability transition (PT) pore by cyclosporin A (CsA) in
combination with Bcl-2 over-expression provided effective
protection from BetA induced apoptosis.
Materials and methods
Chemicals
Betulinic acid (C99% pure, Bioservice Halle) was dissolved
at 4 mg/ml in DMSO and aliquots were stored at -80C.
zVAD.fmk (benzyloxycarbonyl-Val-Ala-Asp-fluorometh-
ylketone), etoposide, TMRE (Tetramethylrhodamine ethyl
ester perchlorate), cyclosporin A and propidium iodide (PI)
were purchased from Sigma–Aldrich. Anti-APO-1 was a
kind gift from Dr. Peter Krammer.
Antibodies
For western blot analysis anti-caspase-3 (AF-605-NA,
R&D and #9662, Cell Signaling) was used as well as an
antibody specific for cleaved capsase-3 (Asp175, Cell
Signaling) for mouse embryonic fibroblasts, furthermore
anti-PARP (#9542, Cell Signaling), anti caspase-7 (#9492,
Cell Signaling), anti-Bak (#06-536, Millipore), anti-Bax
(N-20, Santa Cruz), anti Bcl-XL (B22630, BD; SC-634,
Santa Cruz), and anti-Bcl-2 (N-19, Santa Cruz) were used.
Anti-cytochrome c for FACS staining was obtained from
BD (clone 6H2.B4).
Cells
Jurkat cells over-expressing Bcl-2, Bcl-XL and wild-type
(wt) control cells were obtained from Dr. Jannie Borst
(NKI, Amsterdam), MCF-7/FAS and MCF-7/FAS Bcl-2
or Bcl-XL were obtained from Dr. Marja Ja¨a¨ttela¨ (Danish
Cancer Society, Copenhagen) [18]. FADD-deficient,
Casp-8- deficient and control Jurkat cells (JA3) were
obtained from Dr. John Blenis (Harvard Medical School,
Boston), Bax/Bak DKO MEFs and wild-type control MEFs
were from Dr. Stanley Korsmeyer. APAF-1 and Caspase-9
knockout and wild-type MEFs were from Dr. Tak Mak
(University of Toronto, Canada) and Dr. Richard Flavell
(Yale, New Haven, USA), respectively. SW480 were pro-
vided by J. van Eendenburg and Dr. A. Gorter (department
of Pathology, Leiden University Medical Center, The
Netherlands), A549 were from ATCC, and HCT116 lines
were from Dr. G. C. Chinnadurai (St Louis University
School of Medicine, USA) and Dr. B. Vogelstein (Johns
Hopkins, USA). All cells were cultured in IMDM supple-
mented with 8% FCS, 2 mM L-glutamine, 100 U/ml
penicillin and 100 lg/ml streptomycin.
DNA fragmentation
Apoptotic DNA fragmentation was measured as previously
described [6, 7]. Briefly, cells were resuspended in Nico-
letti buffer containing 50 lg/ml PI for a minimum of 24 h.
Afterwards DNA content was determined in the resulting
nuclei using flow cytometric measurement of PI.
Western blot analysis
Cells were lysed in Triton X-100 buffer on ice and protein
was quantified using a BCA kit from PIERCE according to
manufactures protocol. A volume of 10–15 lg total protein
was loaded per lane for SDS–PAGE and blotted onto
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PVDF transfer membrane (Amersham Biosciences).
Blocking of unspecific binding sites was performed over-
night at 4C in 5% low fat milk powder in PBS/0.2%
Tween-20 (blocking buffer), blots were then incubated
with the primary antibody for 2 h at room temperature in
blocking buffer, washed and incubated in blocking buffer
with a secondary, HRP labeled antibody. For chemilumi-
nescent visualization, ECL from Amersham Biosciences
was used.
Cytochrome c release by FACS staining
Cytochrome c release assay was performed according to the
protocol of Waterhouse [7, 19]. Briefly, cells were trypsini-
zed, washed with PBS and incubated with 50 lg/ml
digitonin in PBS with 100 mM KCl for 5–10 min. Perme-
abilization of the cell membrane was assessed using trypan
blue exclusion. When the majority of the cells in the aliquot
used for trypan blue staining were penetrated by the dye,
cells were fixed in 4% paraformaldehyde in PBS for 30 min,
washed and incubated in blocking buffer (3% BSA, 0.05%
saponin, 0.02% azide in PBS supplemented with normal goat
serum, dilution 1:200) for 1 h at room temparature. Anti-
cytochrome c incubation was done overnight at 4C, cells
were washed three times and FITC conjugated secondary
antibody was applied for 1 h at 4C. After another washing
step cells were analyzed by flow cytometry.
Assessment of mitochondrial membrane potential
Cells were incubated in growth medium containing 25 nM
TMRE for 15–20 min at 37C, resuspended in HEPES
buffer, pH 7.4, containing 25 nM TMRE and analyzed by
flow cytometry.
Results
BetA-induced apoptosis depends on the apoptosome
To determine whether apoptosis is induced in a classical
caspase-dependent fashion, Jurkat cells were treated with
BetA in the presence or absence of the pan-caspase
inhibitor zVAD.fmk. In line with previous observations,
BetA induced caspase-3 and PARP cleavage as well as
DNA fragmentation and all these effects were inhibited in
the presence of 20 lM zVAD.fmk (Fig. 1a) [6, 12, 13].
The death receptor or extrinsic pathway is not involved in
BetA-induced apoptosis [2, 9, 11, 20]. In agreement, Jurkat
cells deficient in either FADD (FAS Associated Death
Domain) or caspase-8, two crucial mediators in the extrinsic
pathway, revealed similar sensitivity to BetA, whereas these
cells were fully protected against CD95-induced apoptosis
(Fig. 1b). These results suggest that BetA is able to induce
caspase activation in a death receptor-independent and
therefore likely a mitochondria dependent fashion. To vali-
date whether the apoptosome, the signaling complex for
capase-9 activation, is crucial for downstream caspase acti-
vation we used cells devoid of a functional apoptosome due
to deletion of either Apaf-1 or caspase-9. MEFs lacking
caspase-9 or Apaf-1 and wild-type MEFs were treated with
various concentrations of BetA and apoptosis induction was
analyzed after 24 h. Importantly, processing of both caspase-
3 and PARP was blocked in caspase-9 deficient cells and in
cells lacking Apaf-1 (Fig. 1c), indicating that the apopto-
some is a key platform for downstream caspase activity in
BetA-treated cells.
Anti-apoptotic Bcl-2 family members partially prevent
BetA-induced apoptosis
Previously, the neuroblastoma cell line SHEP was shown
to become resistant to BetA when over-expressing Bcl-2
[9, 12, 13]. This would fit the role of cytochrome c in the
induction of apoptosis. In agreement with these observa-
tions we detected that BetA-induced DNA fragmentation
after 24 h was reduced, albeit partially, by Bcl-2 over-
expression in Jurkat cells (Fig. 2b, c). Surprisingly, this
protective effect was lost at later time points and after 72 h
of treatment DNA fragmentation was induced as effec-
tively in Bcl-2 over-expressing cells as compared to control
cells (Fig. 2c). In contrast, etoposide-induced DNA frag-
mentation was prevented by Bcl-2 at all time points
analyzed (Fig. 2a). This indicates that the level of Bcl-2
was sufficient to provide protection against a typical
mitochondrial-dependent drug, but that BetA can circum-
vent this protection and BetA induced apoptosis is only
delayed by Bcl-2.
To further dissect the role of the Bcl-2 family in BetA-
induced apoptosis and to generalize these observations we
used different lines expressing high levels of anti-apoptotic
Bcl-2 family members. The breast cancer cell line MCF-7
has been shown to be relatively resistant to BetA-induced
apoptosis as measured by PI exclusion [6] and DNA
fragmentation [9]. Nevertheless, MCF-7 cells are as sen-
sitive as other tumor cells when clonogenic survival is
measured [6]. MCF-7 lacks functional caspase-3 due to a
frameshift mutation [21], which could explain its resistance
to BetA-induced apoptosis. Indeed, when we measured
DNA fragmentation by means of FACS analysis of propi-
dium iodide stained nuclei, we did not observe a sub-G1
peak, which is indicative for DNA fragmentation (data not
shown). To determine whether BetA was incapable of
activating caspases in MCF-7 we also analyzed PARP
cleavage, which is a general substrate for executioner
caspases and is not necessarily impaired in cells lacking
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caspase-3 [22]. Interestingly, PARP was clearly processed
48 h after BetA addition (Fig. 3a). This is likely due to the
activation of caspase-7, which was cleaved after BetA
treatment (Fig. 3a). Similar to Jurkat cells, MCF-7 cells
over-expressing Bcl-2 or Bcl-XL [18] were also clearly
sensitive to BetA-induced caspase-7 cleavage and PARP
processing, although partial protection was evident
(Fig. 3b). Similarly, DNA fragmentation in Ramos cells
over-expressing Bcl-2 or Mcl-1 was not prevented upon
BetA treatment (data not shown), which further
substantiates our conclusion that anti-apoptotic Bcl-2
family members do not provide effective protection against
BetA-induced apoptosis, especially not at later time points.
Bax/Bak double deficient cells are sensitive
to BetA-induced apoptosis
Because expression, interaction and regulation of Bcl-2
family member proteins is complex and can differ in dis-
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Fig. 1 BetA induced apoptosis
depends on the apoptosome.
a Jurkat cells were pretreated
with 20 lM zVAD.fmk for 2 h
before addition of 10 lg/ml
BetA. After 24 h of treatment
cells were subjected to western
blot analysis (lanes 1: non
treated; 2: Betulinic acid; 3:
5 lg/ml etoposide; 4: 1 lg/ml
anti-APO-1). DNA
fragmentation of BetA treated
cells was monitored after 24, 48,
and 72 h. Etoposide and anti-
APO-1 were included as a
control for caspase-3 and PARP
cleavage. b Jurkat control (JA3),
FADD deficient (FADD ko),
and caspase-8 deficient (casp-8
ko) cells were treated with
indicated concentrations of
BetA or anti-APO1 (1 lg/ml)
for 48 h and subjected to
nicoletti analysis. c Wild-type
(wt), caspase-9 knockout (C9),
and Apaf-1 knockout (A) mouse
embryonic fibroblasts (MEF)
were treated with 10 or 15 lg/
ml BetA for 24 h and caspase-3
and PARP cleavage was
analyzed by immunoblotting.
* Statistical significant
difference (t-test) P \ 0.05
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lacking both Bax and Bak. Different models exist
describing the interaction between the pro- and anti-apop-
totic molecules [25], however, it is agreed upon that Bax or
Bak are required for classical cytochrome c release from
the mitochondria and subsequent caspase activation [25,
26]. Indeed, MEFs lacking Bax and Bak (Fig. 4a) were
resistant to starvation-induced apoptosis and death while
wild-type MEFs readily showed caspase-3 activation
(Fig. 4b) and morphological cell death (Fig. 4c). To
determine if BetA-induced apoptosis was still observed in
Bax/Bak DKO, we performed western blot analysis using
antibodies specific for PARP and cleaved caspase-3.
Strikingly both PARP and caspase-3 were processed as
efficiently in the wild-type and Bax/Bak DKO MEFs
(Fig. 4d). This suggests that BetA-induced apoptosis is
activated in a Bax/Bak-independent, but mitochondria-
dependent fashion. To rule out the possibility that these
findings are selective for MEFs we also obtained HCT116
colon cancer cells that were made deficient for both Bax
and Bak [27, 28]. Similar to the MEFs, we observed that
BetA-induced apoptosis was readily induced in cells









































































Fig. 2 Bcl-2 over-expression delays BetA induced apoptosis in
Jurkat cells. a Vector control and Bcl-2 over-expressing cells were
treated with 5 lg/ml etoposide for 24, 48, and 72 h and DNA
fragmentation was measured. b Vector control (ctr) and Bcl-2 over-
expressing (Bcl-2) Jurkat cells were analyzed for Bcl-2 expression by
immunoblot analysis. c Vector control (j) and Bcl-2 over-expressing
(m) Jurkat cells were treated with indicated concentrations of BetA
for 24, 48, and 72 h and DNA fragmentation was assessed.
* Statistical significant difference (t-test) P \ 0.05
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Fig. 3 Bcl-2 or Bcl-XL over-expression partially prevents BetA-
induced apoptosis in MCF-7 cells. a MCF-7 cells were treated with
10 lg/ml BetA for 48 h and PARP processing and caspase-7 cleavage
was assessed. b MCF-7/FAS, MCF-7/FAS Bcl-2, and MCF-7/FAS
Bcl-XL were treated with 10, 15 or 20 lg/ml BetA for 48 h and
immunoblot staining was performed to assess caspase-7 and PARP
cleavage. Immunoblot staining for capsase-7 and PARP was
performed on the same blot
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induces apoptosis independent of these pro-apoptotic Bcl-2
family members.
Cytochrome c is released upon BetA treatment
in Bax/Bak DKO MEFs
Although Bax and Bak appear to be dispensable, the ap-
optosome is crucial for BetA induced apoptosis. Functional
apoptosome formation requires the release of cytochrome c
from the mitochondria. We therefore analyzed whether
cytochrome c was released upon BetA treatment. In
untreated wild-type MEFs cytochrome c was detected at
high levels in the mitochondria using intracellular FACS
analysis (Fig. 5a). Treatment with BetA or FCS starvation
for 24 h resulted in the appearance of a second peak that
signifies cells that have released cytochrome c from their
mitochondria, indicating that BetA and starvation both
induce cytochrome c release. Importantly, cytochrome c
release was also detected in casp-9 and APAF-1 KO MEFs
(data not shown), which shows that their lack of apoptosis
induction is not due to a lack of mitochondrial dysfunction.
As Bax/Bak DKO MEFs undergo apoptosis as efficiently
as wild-type, our results could point to a Bax/Bak-inde-
pendent release of cytochrome c. In agreement, a similar
percentage of Bax/Bak DKO cells displayed cytochrome c
release upon BetA treatment (Fig. 5b). It is important to
note that the level of cytochrome c retained in the mito-
chondria of treated cells appeared slightly higher in Bax/
Bak DKO cells (Fig. 5a). This indicates that the number of
cells with cytochrome c release is the same, but that the
amount of release per cell seems to be less, potentially due
to a lack of amplification. BetA thus releases cytochrome c
in a Bax/Bak-independent fashion.
BetA induced mitochondrial depolarization
and apoptosis is dependent on the PT pore
Combined these observations indicate that apoptosis
induction by BetA is independent of Bax and Bak, but is, at
least partially, affected by Bcl-2 or Bcl-XL over-expres-
sion. This suggests that the pathway induced by BetA is not
a classical mitochondrial Bcl-2 family-dependent one.
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Fig. 4 Bax/Bak DKO MEFs are sensitive to BetA-induced apoptosis.
a Bax and Bak expression was determined in MEFs by immunoblot
analysis. b Cells were functionally tested by washing three times with
PBS and incubation in medium without serum (no FCS) for 24 h and
subsequently tested for the presence of cleaved caspase-3 (casp-3
cleaved). c Wild-type (wt) and Bax/Bak double deficient (DKO)
mouse embryonic fibroblasts were treated with indicated concentra-
tions of BetA for 24 h or subjected to FCS withdrawal and
photographed under a phase-contrast microscope at 9100
magnification. d Wild-type (wt) and Bax/Bak double deficient
(DKO) cells were treated with 10 or 15 lg/ml BetA for 24 h and
immunoblot staining for cleaved caspase-3 and PARP processing was
performed. ERK was used as a control for equivalent protein loading.
e HCT116 CL (Bax KO) and HCT116 DKO (Bax KO and Bak KD)
were incubated with 10 or 15 lg/ml BetA and DNA fragmentation
was tested with nicoletti. Expression of Bax and Bak were validated
by western (not shown)
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Previous findings have indicated that under specific con-
ditions, anti-apoptotic Bcl-2 family members can be
cleaved and thereby converted into pro-apoptotic mole-
cules directly facilitating cytochrome c release [29–31].
Although such a pathway could explain our current
observations, no evidence of cleavage of either Bcl-2 or
Bcl-XL was detected upon BetA treatment (Fig. 6a).
Moreover, the levels of Bcl-2 and Bcl-XL compared to a
control protein ERK-2 were unaffected upon BetA
treatment.
The role of the mitochondrial permeability transition
(PT) pore is controversial in apoptosis signaling. Some
results strongly indicate that it is a secondary effect that
is observed only upon downstream caspase activation,
while other observations rather propose a causal role for
the PT [32]. Opening of the PT pore results in mem-
brane depolarization and is suggested to also lead to
cytochrome c release plus subsequent apoptosis. The
composition of the pore that plays a role in apoptosis is
still a matter of debate. Initial observations indicated that
the pore consists of VDAC, ANT, and cyclophilin D
[33]. However, recent findings on knockouts lacking all
ANT or VDAC forms suggest a more complicated picture
[34, 35], at least when looking at the role of this pore in
apoptosis. Nonetheless, induction of PT can be directly
affected by Bcl-2 family members [36]. We therefore
tested the role of PT using TMRE to measure the mito-
chondrial membrane potential. We found that BetA
induced a significant mitochondrial depolarization in
Jurkat cells after 24 h, which was independent of caspase
activation (Fig. 6b). Importantly, depolarization was
reduced in cells over-expressing Bcl-2 (Fig. 6c). Etopo-
side, a more classical mitochondria-dependent compound,
induced depolarization even more dramatic in control
cells, but this effect was completely blocked by Bcl-2
(Fig. 6d) and to some extent caspase-dependent (not
shown). This again points to the fact that BetA utilizes a
different mechanism to target the mitochondria. To more
directly analyze the involvement of the PT pore in BetA-
induced apoptosis we made use of cyclosporin A (CsA),
an inhibitor of cyclophilin D that prevents opening of the
pore and thereby depolarization [36]. In agreement, CsA
reduced BetA-induced loss of TMRE staining by almost
50% in Jurkat control cells and completely prevented
mitochondrial depolarization (Fig. 6c) and cytochrome c
release (Fig. 6e) in Jurkat-Bcl-2 cells. In contrast, CsA
did not have any protective effects on etoposide treated
cells (Fig. 6d). More importantly, apoptosis as measured
by DNA fragmentation after 72 h of BetA treatment was
substantially inhibited by CsA alone and almost com-
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Fig. 5 BetA induces Bax/Bak
independent cytochrome c
release. Wild-type (wt) and Bax/
Bak double deficient (DKO)
mouse embryonic fibroblasts
(MEFs) were treated for 24 h
with indicated concentrations of
BetA or subjected to FCS
withdrawal and intracellular
staining for cytochrome c
release was performed.
Representative FACS
histograms for cytochrome c
release are shown (a), release
was quantified using CellQuest
software (b)
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BetA induced PT-pore dependent apoptosis is not cell
type dependent
Because Jurkat cells are very sensitive to CsA at higher
concentrations (Fig. 7) it is difficult to assess if CsA could
also provide complete protection to BetA-induced apop-
tosis in cells without Bcl-2 over-expression. In order to test
this and to generalize our findings we used A549 (lung
cancer cell line) and SW480 (colon cancer cell line), which
tolerate higher concentrations of CsA (up to 50 lg/ml).
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Fig. 6 BetA induced mitochondrial depolarization and apoptosis is
dependent on the PT pore. a BetA treated Jurkat wild-type (wt), Bcl-2
or Bcl-XL (XL) over-expressing cells were lysed after 24 h of
treatment and stained with anti Bcl-2 or anti Bcl-XL antibody. Erk is
shown as loading control. b Jurkat wild-type cells were pre-treated
with 20 lM zVAD-fmk for 1 h before BetA addition (10 lg/ml).
After 24 h mitochondrial depolarization was measured using TMRE.
c Jurkat wild-type and Bcl-2 over-expressing cells were pre-incubated
with or without 5 lg/ml cyclosporin A (CsA) for 45 min and exposed
to 10 lg/ml BetA for 24 h. Mitochondrial depolarization was
measured using TMRE. Representative FACS histograms are shown
and depolarization was quantified using CellQuest software. d
Experiment was performed as described above (c) but instead of
treatment with BetA, cells were treated with 5 lg/ml etoposide for
24 h. e Jurkat wild-type and Bcl-2 over-expressing cells were pre-
treated with or without 5 lg/ml cyclosporin A (CsA) for 45 min and
exposed to 10 lg/ml BetA for 24 h and cytochrome c release was
assessed using intracellular FACS staining. f Jurkat cells were treated
as described above (e) and after 72 h DNA fragmentation was
measured. (Statistics: t-test Fig. 6b; one-way ANOVA Fig. 6c–f;
symbols: ns not significant; *P \ 0.05; **P \ 0.01)
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Strikingly, in these cell lines we clearly observed that CsA
completely blocked BetA induced apoptosis, even at high
concentrations (15 lg/ml) of BetA (Fig. 7). Similar results
were obtained using HCT116 cells lacking Bax and Bak
(Fig. 7); again CsA provided very effective protection.
This indicates that the mechanism of BetA induced apop-
tosis depends on the PT pore and is broadly applicable in a
variety of tumor cells.
Discussion
BetA is a very potent compound that is capable of killing a
plethora of tumor cells. Here we demonstrate that BetA
induces apoptosis in a manner that is dependent on the
apoptosome, but is not affected by a lack of pro-apoptotic
Bcl-2 family members Bax and Bak. BetA appears to target
the mitochondrial PT pore directly and mitochondrial
depolarization indeed is shown to be prevented by CsA.
The anti-apoptotic Bcl-2 family members provide some
protection, but this is at best limited and overcome at later
time points. Multiple tumor cell lines have been shown to
resist classical mitochondrial death pathways as they have
a disturbed ratio of pro- and anti-apoptotic Bcl-2 family
members [15]. Our report now indicates that such
disturbances are to a large extent irrelevant for the apop-
tosis induced by BetA.
Previous studies using the neuroblastoma cell line SHEP
have demonstrated BetA-induced apoptosis to be com-
pletely abrogated by Bcl-2 over-expression [12, 13], which
is in apparent contrast with our data. However, the same
group showed that over-expression of Bcl-2 in Jurkat cells
only provided about 65% protection after 24 h treatment
[2]. Similarly, it has been shown in two human glioma cell
lines and in melanoma cells that over-expression of Bcl-2
only partially reduced caspase-3 activity and cell death
after BetA-treatment [11, 20]. This observation is now
corroborated by us, but extended to later time points and
other cell lines. We found that the partial protective effect
is not detected at all at later time points where the sensi-
tivity to BetA in Bcl-2 over-expressing cells and wild-type
cells was similar (Fig. 2c). It is important to note that this
failure to protect is not due to the level of Bcl-2 (Fig. 2b) as
etoposide-induced death is blocked at all time points tested
(Fig. 2a). Previously, Chintharlapalli et al. [37, 38] repor-
ted that BetA directly affects transcription factors sp1, 3,
and 4 and that this would lower transcription of survivin as
well as Bcl-2. As such, BetA could lower Bcl-2 expression
and thereby induce apoptosis. Although this is likely to






























































































Fig. 7 BetA induced PT-pore
dependent apoptosis is not cell
type dependent. Jurkat wildtype,
A549 (lung cancer cell line),
SW480 and HCT116 Bax/Bak
DKO (colon cancer cell lines)
were pre-treated for 1 h with
increasing concentrations of
CsA and subjected to 10 or
15 lg/ml BetA for 48 h after
which DNA fragmentation was
assessed
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believe that this is the explanation for the differential
sensitivity that we observe between BetA and etoposide.
First and most important, Bcl-2 and Bcl-XL in our system
are not dependent on their endogenous promoter, but on the
strong CMV or EBV promoter and are thus not affected by
sp1, 3, 4 down regulation. Secondly, even in the non-over-
expressing Jurkat lines, we do not observe a decrease in
Bcl-2 or Bcl-XL expression 24 h after BetA treatment.
The Bcl-2 independency of our system is even further
supported by our observation that BetA-induced apoptosis
is independent of the pro-apoptotic Bcl-2 family members
Bax and Bak. In Bax/Bak DKO MEFs caspase-3 and PARP
processing was induced with equal efficiency as in wild-
type cells (Fig. 4d). Previously, Liby et al. [39] showed
that Bax/Bak DKO MEFs were sensitive to BetA deriva-
tives, but resisted BetA induced apoptosis. It is difficult to
provide a rational for this discrepancy, especially as we
also observe BetA-induced apoptosis in Bax/Bak deficient
HCT-116 cells. We do observe a slight difference in
cytochrome c release though, which is less pronounced
in Bax/Bak DKO MEFs (Fig. 5a), but importantly, the
amount of cells releasing cytochrome c is identical
(Fig. 5b). The small difference in cytochrome c release is
therefore either the result of less mitochondria per cell that
release cytochrome c or that less cytochrome c is released
per mitochondria. We believe this signifies the absence of
an amplification loop initiated by active caspase-3, which
cleaves Bid and thereby targets the mitochondria to induce
maximal release. In agreement, caspase-8 processing
occurs as an event downstream of the mitochondria in
BetA treated neuroblastoma cells [12], and both caspase-8
and Bid-cleavage were shown for BetA treated Jurkat cells
[2]. Bcl-2 over-expression and Bax/Bak deficiency could
therefore disallow this amplification and cells would
thereby show less cytochrome c release.
Mitochondrial membrane depolarization is a heavily
debated issue in apoptosis signaling. There is agreement on
its occurrence, but the causal role for cytochrome c release
is clearly disputed [32]. We show that etoposide-induced
loss of TMRE is blocked by Bcl-2 (Fig. 6d), and that BetA-
induced depolarization is only partially prevented by Bcl-2
(Fig. 6c) but appears to serve a causal role as suggested by
the inhibition of apoptosis by CsA (Fig. 6f). These obser-
vations point to a model in which BetA directly targets the
pore and thereby allows cytochrome c release and down-
stream caspase activation. Bcl-2 family members have
been shown to directly bind VDAC and regulate its pore
forming activity. The pro-apoptotic member Bax promotes
opening, while the anti-apoptotic members induce closure
[40]. A direct Bcl-2 family member-independent opening
of the PT pore by BetA is consistent with our current
observations. These would be independent of Bax and Bak,
but could be hampered by Bcl-2 or Bcl-XL, which
independently promote closure of the pore [41]. The fact
that CsA prevents pore opening and reduces apoptosis
significantly, combined with the observation that this effect
is complete in Bcl-2 over-expressing Jurkat cells adds to
this hypothesis. It is important to note though that higher
concentrations of CsA are capable of complete protection
against BetA-induced apoptosis in three separate tumor
lines. In Jurkat cells we failed to obtain full protection due
to the high toxicity of CsA itself on these cells. However,
A549 lung carcinoma cells, SW480 colon carcinoma cells
as well as Bax/Bak deficient HCT-116 colon carcinoma
cells all withstood CsA up to concentrations of 50 lg/ml
and showed complete inhibition of BetA-induced apoptosis
by CsA. Previous observations have shown that bongkrekic
acid, a separate PT pore inhibitor, can also prevent BetA-
induced cytotoxic effects [13] and thus support this model
even further. We therefore believe that BetA targets the PT
pore directly and thereby induces mitochondrial-dependent
apoptosis. Other compounds, such as gossypol [42],
A23187/ArA [43], and chelerythrine [44] have recently
also been shown to induce Bax/Bak-independent cyto-
chrome c release. Although for A23187/ArA-induced
release this is suggested to be a serine protease dependent
mechanism, chelerythrine, which shares some structural
similarity with BetA, can induce release from isolated
mitochondria. Although chelerythrine was developed as a
Bcl-XL inhibitor, it also appears to induce mitochondrial
permeabilization and apoptosis in Bax/Bak DKO cells,
which is prevented by CsA [44]. Combined, this may point
to a mechanism in which the lipophilic characteristics of
these compounds provide them with the means to target the
outer mitochondrial membrane and thereby potentially
affect the PT pore. In agreement with this idea is the
observation that the PT pore opening is affected by the
cholesterol content of the outer mitochondrial membrane
[32]. As cholesterol and BetA are structurally related, BetA
could either modify this effect or have similar activity
itself. Importantly, some tumor cells have been shown to
contain higher cholesterol levels in their mitochondrial
membrane and lowering this sensitizes them to apoptosis
[32]. More importantly, reconstituted PT pores in artificial
membranes localize to cholesterol areas and can be opened
using long chain fatty acids [45], indicating that lipids have
a strong modulating effect on the pore.
Although these data provide an appealing explanation
for the broad effects of BetA on tumor cells, it still remains
difficult to understand why it is without effect on
untransformed cells. As mentioned, the lipid content of the
mitochondria in tumor cells may be different to some
extent, but this is unlikely to explain the selectivity for
tumor cells. Especially as the changes observed in tumor
cells rather prevent then facilitate apoptosis induction. It is
possible though that another component associated with the
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PT-pore is a crucial determinant in the toxicity exerted by
BetA. This component, hexokinase is associated with the
pore on the cytoplasmic side and regulates pore opening as
well as the level of glycolysis in a cell [46]. It is well
established that tumor cells mainly utilize glycolysis for
their ATP generation. This so called Warburg effect is
potentially regulated by a differential expression level of
hexokinase II in tumor versus normal cells [47]. Inactiva-
tion of hexokinase II using 3-bromopyruvate displays
similar tumor selectivity as BetA [46].
In summary, we conclude that our study provides an
explanation as to why BetA is a very effective and broadly
applicable anti-cancer agent, even against tumor cells
which have acquired resistance to other, Bcl-2 family
dependent, apoptosis inducing treatments. Future experi-
ments will provide more mechanistic insight into the exact
mechanism by which BetA modulates the PT-pore and
whether the tumor selectivity involves PT pore sensitivity
and/or hexokinase activity.
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